Business
Scholar Rock Appoints Edward (Ted) Myles as Chief Financial Officer and Head of Business Operations
- Financial and operational leader brings deep expertise from across clinical and commercial stage biopharmaceutical companies CAMBRIDGE, Mass.--(BUSINESS
About this update from Scholar Rock Holding Corporation
[{"type":"text","content":"\n- Financial and operational leader brings deep expertise from across clinical and commercial stage biopharmaceutical companies\n\n CAMBRIDGE, Mass.--(BUSINESS WIRE)--\nScholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced the appointment of Edward (Ted) Myles, as Chief Financial Officer and Head of Business Operations, responsible for finance, investor relations, corporate communications, IT and facilities. He brings more than 20 years of experience as a senior finance and operations executive with development and commercial stage biopharmaceutical companies. Mr. Myles has served on Scholar Rock’s Board of Directors, including as chair of the audit committee and a member of the compensation committee since November 2018. He is stepping down from the Board of Directors in connection with his appointment to the executive leadership team.\nThis press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200716005264/en/Ted Myles (Photo: Business Wire)\n\n“Ted’s deep industry knowledge and extensive leadership experience across finance, operations, and strategic development and implementation will be instrumental in driving the execution of the Company’s key initiatives,” said Tony Kingsley, Incoming CEO of Scholar Rock. “His areas of expertise strongly complement the capabilities of the existing team as we build on the achievements of our scientific platform and progress our lead product candidates towards late-stage development and commercialization for patients in need.”\n\n\n“Having served on the Company’s Board of Directors the past 18 months, I have witnessed the immense potential of our scientific platform and clinical programs and have a high degree of confidence in the team’s ability to execute,” said Ted Myles. “This is a pivotal time for Scholar Rock as we advance two in-house product candidates towards important clinical milestones and I am thrilled to work alongside the leadership team to help prepare for the next stage of the company’s evolution.”\n\n\nTed Myles most recently served as Chief Financial Officer and Chief Operating Officer of AMAG Pharmaceuticals, Inc. Prior to joining AMAG, he served as CFO and COO at Ocata Therapeutics, Inc....